ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
After four months of delays, DuPont has completed its $6.6 billion purchase of enzyme and food ingredient maker Danisco. Separately, after five months, Thermo Fisher Scientific has completed the $2.1 billion purchase of Dionex, a manufacturer of liquid and ion chromatography scientific instruments. In DuPont’s case, first regulatory approvals and then shareholder resistance to the original offering price of $6.3 billion delayed completion of the Danisco deal. Despite backing from the Danish firm’s management and two offer extensions, only 48% of Danisco shareholders had tendered their shares by late April. Faced with these results, on April 29 DuPont made its “best and final offer” of $6.6 billion, a 5% premium over the original one. In addition, the firm lowered the number of Danisco shares it required to complete the deal from 90% to 80%. The increased offer did the trick: By May 13, more than 92% of shareholders had accepted the deal. For Thermo Fisher, the sticking point was gaining regulatory approval for the deal, which the firm completed on May 13. Less than a week later, Thermo Fisher acquired Sterilin, a U.K.-based provider of single-use products for life sciences customers, from private equity firm Nova Capital Management. Sterilin has annual sales of $35 million and 270 employees.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X